APA (7th ed.) Citation

Shuhua Shen, Kungen Wang, Yihui Zhi, & Yue Dong. (2022). Gypenosides counteract hepatic steatosis and intestinal barrier injury in rats with metabolic associated fatty liver disease by modulating the adenosine monophosphate activated protein kinase and Toll-like receptor 4/nuclear factor kappa B pathways. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Shuhua Shen, Kungen Wang, Yihui Zhi, and Yue Dong. Gypenosides Counteract Hepatic Steatosis and Intestinal Barrier Injury in Rats with Metabolic Associated Fatty Liver Disease by Modulating the Adenosine Monophosphate Activated Protein Kinase and Toll-like Receptor 4/nuclear Factor Kappa B Pathways. Taylor & Francis Group, 2022.

MLA (9th ed.) Citation

Shuhua Shen, et al. Gypenosides Counteract Hepatic Steatosis and Intestinal Barrier Injury in Rats with Metabolic Associated Fatty Liver Disease by Modulating the Adenosine Monophosphate Activated Protein Kinase and Toll-like Receptor 4/nuclear Factor Kappa B Pathways. Taylor & Francis Group, 2022.